INMB · Inmune Bio, Inc. · Financials
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern. ... Because management's plans have not yet been finalized and are not within the Company's control, the implementation of such plans cannot be considered probable. As a result, the Company has concluded that management's plans do not alleviate substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | $50K | $14K | $155K | $374K | $181K | $11K | — | $0 | $0 | |
| $16.66M | $20.66M | $33.17M | $20.27M | $17.07M | $20.54M | $5.92M | $3.28M | $3.35M | $435.36K | |
| $10.14M | $10.26M | $9.48M | $9.62M | $9.26M | $8.79M | $6.32M | $6.02M | $9.09M | $546.12K | |
| $20.2M | $47.43M | $42.65M | $29.9M | $26.33M | $29.33M | $12.24M | $7.76M | $12.44M | $981.48K | |
| -$20.2M | -$47.38M | -$42.64M | -$29.74M | -$25.95M | -$29.15M | -$12.23M | -$7.76M | -$12.44M | -$981.48K | |
| — | -94766% | -304535.71% | -19187.74% | -6938.77% | -16106.63% | -111163.64% | — | — | — | |
| $0 | — | $357K | $2.28M | $2.01M | — | — | — | — | — | |
| $1.78M | $1.45M | $553K | -$267K | -$1.35M | -$1.19M | $129K | $77.69K | — | $149.99K | |
| — | $45.93M | $42.08M | $30.01M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $0 | $0 | |
| -$18.42M | -$45.93M | -$42.08M | -$30.01M | -$27.3M | -$30.34M | -$12.1M | -$7.68M | -$12.44M | -$831.49K | |
| — | -91866% | -300585.71% | -19360% | -7299.2% | -16762.43% | -109990.91% | — | — | — | |
| -$18.48M | -$46.1M | -$41.86M | -$30.11M | -$28M | -$30.35M | -$12.08M | -$7.69M | -$12.47M | -$796.6K | |
| USD/shares | -$0.63 | -$1.86 | -$2.11 | -$1.67 | -$1.52 | -$1.88 | — | — | — | — |
| USD/shares | -$0.63 | -$1.86 | -$2.11 | -$1.67 | -$1.52 | -$1.88 | — | — | — | — |
| shares | — | 24.76M | 19.94M | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 8.68M | 6.56M |
| shares | — | 24.76M | 19.94M | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 8.68M | 6.56M |
Debt Profile
Annual debt figures are established from annual reports and updated by subsequent interim reports and event disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Reported debt balances
Balances may overlap and are not added together. Each row keeps its reported scope and date.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Long-term debt | 2025-06-30 | USD 15,000,000 | 10-Q filed 2025-08-07 |
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 292 similar-size Biotechnology companies (of 532 listed).